公开(公告)号：US11285190B2

公开(公告)日：2022-03-29

申请号：US15567762

申请日：2016-04-18

Applicant: The Board of Regents of the University of Texas System

Inventor： Sean Morrison ,  Rui Yue

IPC: A61K38/18 ,  A61P19/08 ,  A61K38/29 ,  A61K45/06 ,  A61P35/04 ,  A61P19/10

Abstract: The present disclosure describes the C-type lectin CLEC11a as a bone growth factor. Clec11a-deficient mice showed reduced bone volume and mineralization, while bone resorption remained unchanged. Administration of recombinant Clec11a systemically promoted bone formation in mice at risk for osteoporosis.

公开(公告)号：US20200297816A1

公开(公告)日：2020-09-24

申请号：US16864872

申请日：2020-05-01

Applicant: The Board of Regents of the University of Texas System

Inventor： Sean Morrison ,  Rui Yue

IPC: A61K38/18 ,  A61K38/29 ,  A61K45/06 ,  A61P19/08 ,  A61P35/04 ,  A61P19/10

Abstract: The present disclosure describes the C-type lectin CLEC11a as a bone growth factor. Clec11a-deficient mice showed reduced bone volume and mineralization, while bone resorption remained unchanged. Administration of recombinant Clec11a systemically promoted bone formation in mice at risk for osteoporosis.

公开(公告)号：US11890320B2

公开(公告)日：2024-02-06

申请号：US16864872

申请日：2020-05-01

Applicant: The Board of Regents of the University of Texas System

Inventor： Sean Morrison ,  Rui Yue

IPC: A61K38/18 ,  A61P19/08 ,  A61K38/29 ,  A61K45/06 ,  A61P35/04 ,  A61P19/10

CPC classification number: A61K38/18 ,  A61K38/29 ,  A61K45/06 ,  A61P19/08 ,  A61P19/10 ,  A61P35/04 ,  A61K38/29 ,  A61K2300/00

Abstract: The present disclosure describes the C-type lectin CLEC11a as a bone growth factor. Clec11a-deficient mice showed reduced bone volume and mineralization, while bone resorption remained unchanged. Administration of recombinant Clec11a systemically promoted bone formation in mice at risk for osteoporosis.

公开(公告)号：US09561245B2

公开(公告)日：2017-02-07

申请号：US14019327

申请日：2013-09-05

Applicant: The Board of Regents of the University of Texas System

Inventor： Sean Morrison ,  Elena Piskounova ,  Ugur Eskiocak

IPC: A61K31/7048 ,  A61K31/585 ,  A61K31/506 ,  A61K31/437 ,  A61K31/404

CPC classification number: A61K31/7048 ,  A61K31/404 ,  A61K31/437 ,  A61K31/506 ,  A61K31/585 ,  A61K2300/00

Abstract: The present invention relates to combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such therapies in include BRAF inhibitors such as PLX 4720 and PLX 4734 in combination with RO 31-8220, bafetinib or cardiac glycosides.

Abstract translation: 本发明涉及黑素瘤，特别是转移性黑素瘤的组合疗法。 用于此类治疗的药物包括BRAF抑制剂如PLX 4720和PLX 4734与RO 31-8220，bafetinib或强心苷组合。

公开(公告)号：US09572828B2

公开(公告)日：2017-02-21

申请号：US14280376

申请日：2014-05-16

Applicant: The Board of Regents of the University of Texas System

Inventor： Sean Morrison ,  Ugur Eskiocak

IPC: A61K31/4985 ,  A61K31/7048 ,  A61K31/519 ,  A61K38/20 ,  A61K38/21 ,  A61K45/06

CPC classification number: A61K31/7048 ,  A61K31/4985 ,  A61K31/519 ,  A61K38/2013 ,  A61K38/21 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such therapies in include MEK inhibitors combination with cardiac glycosides.

Abstract translation: 本发明涉及黑素瘤，特别是转移性黑素瘤的组合疗法。 用于此类疗法的药物包括与强心苷组合的MEK抑制剂。